Results 31 to 40 of about 27,592 (211)

Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway

Journal of Pharmacological Sciences, 2014
.: Proliferation of vascular smooth muscle cells (VSMCs) contributes to the development of atherosclerosis. Ezetimibe is a new lipid lowering agent that inhibits cholesterol absorption.
Li Qin, Yun-Bo Yang, Yi-Xin Yang, Yong-Zhen Gong, Xiao-Ling Li, Gui-Yuan Li, Hong-Dan Luo, Xue-Jiao Xie, Xi-Long Zheng, Duan-Fang Liao   +9 more
doaj   +1 more source

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations

Pharmaceutics, 2022
Two active pharmaceutical ingredients (APIs) with limited solubility, simvastatin and ezetimibe, prepared as a drug-drug solid dispersion (SD) was evaluated for physicochemical, microstructural, and aqueous dissolution properties.
Agata Górniak, Adrianna Złocińska, Mateusz Trojan, Adrianna Pęcak, Bożena Karolewicz   +4 more
doaj   +1 more source

Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe

Journal of Lipid Research, 2005
Consumption of plant sterols and treatment with ezetimibe both reduce cholesterol absorption in the intestine. However, the mechanism of action differs between the two treatments, and the consequences of combination treatment are unknown.
Lily Jakulj, Mieke D. Trip, Thomas Sudhop, Klaus von Bergmann, John J.P. Kastelein, Maud N. Vissers   +5 more
doaj   +1 more source

Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects

BMC Pharmacology and Toxicology, 2023
Background Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of hypercholesterolemia.
Feifei Sun, Yanping Liu, Ting Li, Pingping Lin, Xin Jiang, Xin Li, Chenjing Wang, Xiaomeng Gao, Yaping Ma, Yao Fu, Yu Cao   +10 more
doaj   +1 more source

Ameliorative impact of ezetimibe on gentamicin-induced kidney damage; A histopathological perspective study [PDF]

Journal of Nephropathology, 2022
Introduction: Gentamicin, despite its beneficial effects, has significant nephrotoxic effects that are observed in 20% of the patients. Ezetimibe is recognized as an inhibitor of cholesterol absorption.
Elham Emami, Ali Hasanpour Dehkordi, Ahmadreza Maghsoudi, Hamid Nasri, Alireza Vahedi   +4 more
doaj   +1 more source

Glycaemic effects of non-statin lipid-lowering therapies [PDF]

, 2016
Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core   +1 more source

Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI–MS/MS and its application to a pharmacokinetic study

Journal of Pharmaceutical Analysis, 2014
A simple, sensitive and specific liquid chromatography–tandem mass spectrometry method was developed for simultaneous quantification of ezetimibe and simvastatin in rat plasma.
Sireesha R. Karanam, Prakash Katakam, Babu R. Chandu, Nagiat T. Hwisa, Shanta K. Adiki   +4 more
doaj   +1 more source

The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease [PDF]

, 2017
Due to the epidemic of obesity across the world, nonalcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disorders in children and adolescents.
Anania, Caterina, Lavorato, Michela, Perla, Francesco Massimo, Prelati, Maurizia, Visicchio, Daniele   +4 more
core   +2 more sources

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj   +1 more source

Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease [PDF]

, 2018
INTRODUCTION: Familial hypercholesterolemia (FH) is an inherited disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) associated with premature cardiovascular disease. METHODS: Using the data from the START
A., Gulizia, Arca, M., Bosco, B., Callerame, M., Colivicchi, F., De Luca, L, Di, Lenarda, Gonzini, L., Lettica, G. V., Lucci, D., Temporelli, P. L.   +10 more
core   +1 more source